Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039819 | 0.90 | MMP13 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1KCNH2 | |
| SCHEMBL7040564 | 0.84 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL7033297 | 0.83 | ALDH1A1 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1KCNH2 | |
| SCHEMBL7036485 | 0.76 | SMN1; SMN2 (0.45) | MEN1KMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6097001 | 0.75 | ALDH1A1 (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1KCNH2 | |
| SCHEMBL3954923 | 0.74 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1L3MBTL1LMNA | |
| SCHEMBL7034702 | 0.73 | MMP2 (0.55) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL7034277 | 0.73 | HPGD (0.48) | KMT2ASMN1; SMN2ALDH1A1HTTMAPT | |
| SCHEMBL7036358 | 0.73 | MMP2 (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1KCNH2 | |
| SCHEMBL7039812 | 0.72 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | disclosed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | MMP2, CTSH, TIMP3 | MEN1 3457/4885KMT2A 1406/4885SMN1; SMN2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.